Using florzolotau (18F), an originally developed tau PET tracer, we longitudinally assessed patients with progressive supranuclear palsy and demonstrated that faster tau accumulation in the globus pallidus is associated with faster clinical progression. These findings support tau PET as an objective biomarker for disease progression and therapeutic development.